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Linsitinib is a potent small‐molecule tyrosine kinase inhibitor of the human IGF‐1R, with a half maximal inhibitory concentration (IC~50~) of 35 nmol/L, and the homologus insulin receptor, with an IC~50~ of 75 nmol/L. The drug is selective for these targets \[[1](#onco12622-bib-0001){ref-type="ref"}\].

Irinotecan is a topoisomerase I inhibitor that is U.S. Food and Drug Administration approved for the treatment of colorectal cancer with compendia for reimbursement including non‐small cell lung, gastroesophageal, cervical, and ovarian cancers.

The combination of linsitinib and irinotecan was selected for further evaluation based on preclinical data suggesting a synergistic interaction between the drugs \[[2](#onco12622-bib-0002){ref-type="ref"}\].

Eligible patients with refractory advanced cancer, and for which irinotecan is in the compendia for reimbursement, were treated with linsitinib, administered by mouth, and irinotecan, by intravenous (IV) infusion, in 21‐day cycles at three dose levels. Once the maximum tolerated dose (MTD) was defined, expansion of this dose level was planned in patients with advanced colorectal cancer. A potential predictive biomarker, the linsitinib integrated classifier score \[[3](#onco12622-bib-0003){ref-type="ref"}\], was to be evaluated in this cohort.

A total of 18 patients were enrolled in the trial at a single site. One of seven evaluable patients in the second cohort experienced a dose‐limiting toxicity (DLT) of grade 3 nausea/vomiting requiring hospitalization. A DLT of grade 3 febrile neutropenia/grade 4 neutropenia was documented in one of seven patients treated in cohort 3. Linsitinib 450 mg and irinotecan 125 mg/m^2^ was determined to be the MTD.

The most common toxicities at least possibly related to treatment and occurring in at least 10% of cycles were nausea, vomiting, fatigue, and anorexia. Hyperglycemia and QTc prolongation were considered adverse events of special interest, although no events above grade 1 severity were documented.

Eight patients (47%) had stable disease. No responses were documented, although one patient with metastatic rectal cancer had a 23% decrease in tumor burden and was treated for 18 cycles. Seven patients (41%) had progressive disease.

Although the combination of linsitinib and irinotecan was determined to be safe at the MTD, the study was halted at this point due to termination of linsitinib development. Thus, the expansion cohort and analysis of the linsitinib integrated classifier and other pharmacodynamic and pharmacokinetic data were not completed.
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**Disease**Advanced colorectal, non‐small cell lung, gastroesophageal, cervical, and ovarian cancer**Stage of Disease/Treatment**Metastatic/advanced**Prior Therapy**No designated number of regimens**Type of Study -- 1**Phase I**Type of Study -- 2**3 + 3**Primary Endpoint**Maximum tolerated dose**Primary Endpoint**Safety**Primary Endpoint**Tolerability**Secondary Endpoint**Preliminary antitumor activity**Secondary Endpoint**Correlative endpoint**Additional Details of Endpoints or Study Design** An expansion cohort of patients with advanced colorectal cancer who had failed a prior oxaliplatin‐containing regimen was planned at the MTD. These patients were to be assigned to one of two cohorts according to a candidate predictive biomarker---the linsitinib integrated classifier score. The linsitinib integrated classifier is a k‐Top Scoring Pair classifier, developed from gene array data from sensitive and resistant preclinical colorectal cancer (CRC) models, used in combination with IGF‐1R fluorescence in situ hybridization and *KRAS* mutation status. This classifier was a successful predictor of sensitivity to linsitinib therapy in preclinical patient‐derived CRC xenograft models \[[3](#onco12622-bib-0003){ref-type="ref"}\]. Patients in the expansion cohort with a score of 4/5 or above were to be assigned to a single‐agent linsitinib arm, whereas those with lower scores were to receive treatment with single‐agent irinotecan, with linsitinib added to this regimen at the time of progression. **Investigator\'s Analysis**Drug tolerable, hints of efficacy
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Drug 1 Generic/Working NameLinsitinib/OSI‐906Trade Name Company NameOSI PharmaceuticalsDrug TypeSmall moleculeDrug ClassInsulin‐like glistItemPairth factors---IGF‐1R and IGF‐2Dosemg per flat doseRoutep.o.Schedule of AdministrationFor cycle 1, patients were treated with a single dose of linsitinib on day −3, with further dosing days 2--4, 8--10, and 15--17. Patients received a single‐dose of linisitinb on days 1--3, 8--10, and 15--17 for all additional cycles.Drug 2 Generic/Working NameIrinotecanTrade NameCamptosarCompany NamePfizerDrug TypeOtherDrug ClassTopoisomerase IDosemg/m^2^RouteIVSchedule of AdministrationDay 1 and 8 every 21 days for all treatment cycles.
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Number of Patients, Male10Number of Patients, Female8StageIVAgeMedian (range): 51 (28--69)Number of Prior Systemic TherapiesMedian (range): 2 (1--6)Performance Status: ECOG0 --- 91 --- 92 --- 03 --- 0Unknown --- 0Cancer Types or Histologic SubtypesColon 10Rectal 4Esophageal 2Cervical 1Ovarian 1
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TitleTotal patient populationNumber of Patients Screened21Number of Patients Enrolled18Number of Patients Evaluable for Toxicity17Number of Patients Evaluated for Efficacy12Evaluation MethodRECIST 1.0Response Assessment CR*n* = 0 (0%)Response Assessment PR*n* = 0 (0%)Response Assessment SD*n* = 8 (53%)Response Assessment PD*n* = 7 (47%)(Median) Duration Assessments Response Duration12 weeks(Median) Duration Assessments Duration of Treatment6 weeks

 {#onco12622-sec-1011}

biography image

Best percentage change from baseline in sum of longest diameters

Adverse Events {#onco12622-sec-1012}
==============

imageJohn Wiley & Sons, Ltd.[^1]

Serious Adverse Events {#onco12622-sec-1013}
======================

imageJohn Wiley & Sons, Ltd.[^2]
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Assessment, Analysis, and Discussion {#onco12622-sec-1016}
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CompletionStudy terminated before completionTerminated ReasonCompany stopped developmentInvestigator\'s AssessmentDrug tolerable, hints of efficacy
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Although this study was discontinued early due to halting of linsitinib development, the dose‐escalation data do provide important safety information regarding this insulin‐like growth factor‐1 receptor (IGF‐1R) inhibitor in combination with irinotecan chemotherapy. In this study, the maximum tolerated dose of linsitinib was 450 mg daily on days 1--3 every 7 days in combination with irinotecan 125 mg/m^2^ days 1 and 8 of a 21‐day cycle. Overall, this combination was well tolerated across predefined dose levels, with most adverse events (AEs) grade 1--2 in severity.

Hyperglycemia is the primary class‐effect toxicity of IGF‐1R small‐molecule tyrosine kinase inhibitors (TKIs) due to insulin receptor (IR) cross‐targeting at clinically relevant doses \[[4](#onco12622-bib-0004){ref-type="ref"}\], \[[5](#onco12622-bib-0005){ref-type="ref"}\]. However, such AEs were overall mild in severity in this study, with no events meeting criteria for dose‐limiting toxicity (DLT) in this patient population. It is possible that no significant hyperglycemia was documented in this study because lower doses of linsitinib were used for combination dosing with irinotecan, and patients with baseline glucose elevations were excluded from participation. Elevation in liver function tests has also been documented in phase I studies of linsitinib alone and in combination with everolimus \[[5](#onco12622-bib-0005){ref-type="ref"}\], \[[6](#onco12622-bib-0006){ref-type="ref"}\], and although grade 3 elevation was observed in one patient on this trial, it was attributed to underlying disease and improved to grade 1 following stenting of a malignant stricture. Although not considered a class effect, QTc prolongation has been a DLT in other studies of linsitinib \[[4](#onco12622-bib-0004){ref-type="ref"}\], \[[5](#onco12622-bib-0005){ref-type="ref"}\], \[[7](#onco12622-bib-0007){ref-type="ref"}\]. In this trial, no grade 3 or greater prolongation of QTc was observed. Unfortunately, due to early discontinuation of this clinical trial, we do not have pharmacokinetic data to further explore its relationship to this toxicity profile.

The early closure of this study and halting of linsitinib development is representative of the fate of IGF‐1R inhibitors in oncology drug development in the last 10 years. Although initially a promising target based on data from various preclinical studies, nearly 40 clinical trials evaluating IGF‐1R monoclonal antibodies, IGF‐1/2‐targeting antibodies, and IGF‐1R/IR small molecule TKIs did not demonstrate a significant clinical benefit in any tumor type \[[8](#onco12622-bib-0008){ref-type="ref"}\], \[[9](#onco12622-bib-0009){ref-type="ref"}\].

This includes studies evaluating IGF‐1R inhibitors in colorectal cancer, with both single‐agent trials \[[10](#onco12622-bib-0010){ref-type="ref"}\] and combination studies with FOLFIRI \[[11](#onco12622-bib-0011){ref-type="ref"}\], panitumumab \[[12](#onco12622-bib-0012){ref-type="ref"}\], cetuximab/irinotecan \[[13](#onco12622-bib-0013){ref-type="ref"}\], and everolimus \[[6](#onco12622-bib-0006){ref-type="ref"}\] negative for a significant clinical benefit to patients. However, there were outlier patients across these studies who did achieve partial response or prolonged progression‐free survival on such therapy. It thus remains possible that a subset of colorectal cancer (CRC) patients may still benefit from IGF‐1R inhibitor therapy, although clearly a predictive biomarker is required to select such patients.

An important goal of the expansion cohort of this study was to explore this possibility in patients with advanced CRC; in this case using an integrated classifier to predict response to linsitinib therapy based on *k*‐Top Scoring Pair in combination with *KRAS* mutation status and IGF‐1R fluorescence in situ hybridization. Unfortunately, this attempt to identify a predictive biomarker for IGF‐1R targeted therapy came too late in the evaluation of this drug class, and the development of linsitinib was terminated before the classifier was explored in human patients.

Due to discontinuation of development of the majority of IGF‐1R inhibitors, there have been few other efforts to identify a biomarker predictive of activity within or across tumor types. However, a small number of ongoing clinical trials continue to evaluate this target in select tumor types thought to be dependent on IGF‐1R signaling, with the greatest interest in subtypes of sarcoma. Hopefully these and other ongoing studies specifically evaluating potential biomarkers of IGF‐1R inhibitor activity (NCT0271185, NCT02719041, NCT02916394) will lead to the identification of a predictive biomarker that will provide better identification of patients likely to benefit from IGF‐1R inhibition in the broader cancer patient population, as was an initial aim of this clinical trial.

[ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: [NCT01016860](https://clinicaltrials.gov/ct2/show/NCT01016860)

**Sponsor(s)**: Stephen Leong

**Principal Investigator**: Stephen Leong

**IRB Approved**: Yes

[Click here to access other published clinical trials](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results).

Disclosures {#onco12622-sec-0018}
===========

**Jennifer R. Diamond:** Merck, Bristol‐Meyers Squibb, Bayer, Taiho, Immunomedics, Medimmune, Takeda. The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board

[^1]: All AEs in all cycles occurring in at least 10% of patients.Abbreviations: AGC, absolute granulocyte count; ANC, absolute neutrophil count; NC/NA, no change from baseline/no adverse event.

[^2]: The five documented Serious Adverse Events occurred in five unique patients.
